Catalyst Pharmaceuticals, Inc. (DELISTED) (CPRX:DL)
31.49
0.00 (0.00%)
USD |
NASDAQ |
Jul 24, 16:00
Catalyst Pharmaceuticals Price to Book Value : 3.799 for July 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| July 24, 2026 | 3.799 |
| July 23, 2026 | 3.799 |
| July 22, 2026 | 3.799 |
| July 21, 2026 | 3.799 |
| July 20, 2026 | 3.799 |
| July 17, 2026 | 3.799 |
| July 16, 2026 | 3.799 |
| July 15, 2026 | 3.799 |
| July 14, 2026 | 3.799 |
| July 13, 2026 | 3.798 |
| July 10, 2026 | 3.797 |
| July 09, 2026 | 3.797 |
| July 08, 2026 | 3.797 |
| July 07, 2026 | 3.799 |
| July 06, 2026 | 3.800 |
| July 02, 2026 | 3.794 |
| July 01, 2026 | 3.793 |
| June 30, 2026 | 3.792 |
| June 29, 2026 | 3.796 |
| June 26, 2026 | 3.800 |
| June 25, 2026 | 3.791 |
| June 24, 2026 | 3.791 |
| June 23, 2026 | 3.788 |
| June 22, 2026 | 3.786 |
| June 18, 2026 | 3.786 |
| Date | Value |
|---|---|
| June 17, 2026 | 3.788 |
| June 16, 2026 | 3.782 |
| June 15, 2026 | 3.785 |
| June 12, 2026 | 3.784 |
| June 11, 2026 | 3.785 |
| June 10, 2026 | 3.781 |
| June 09, 2026 | 3.781 |
| June 08, 2026 | 3.774 |
| June 05, 2026 | 3.773 |
| June 04, 2026 | 3.775 |
| June 03, 2026 | 3.774 |
| June 02, 2026 | 3.773 |
| June 01, 2026 | 3.773 |
| May 29, 2026 | 3.768 |
| May 28, 2026 | 3.775 |
| May 27, 2026 | 3.779 |
| May 26, 2026 | 3.780 |
| May 22, 2026 | 3.772 |
| May 21, 2026 | 3.774 |
| May 20, 2026 | 3.770 |
| May 19, 2026 | 3.766 |
| May 18, 2026 | 3.768 |
| May 15, 2026 | 3.762 |
| May 14, 2026 | 3.759 |
| May 13, 2026 | 3.759 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 24.11 |
| Indivior Pharmaceuticals, Inc. | -- |
| Exelixis, Inc. | 7.655 |
| United Therapeutics Corp. | 3.458 |
| Krystal Biotech, Inc. | 7.754 |
Price to Book Value Related Metrics
| PE Ratio | 18.10 |
| PS Ratio | 6.712 |
| PEG Ratio | 1.642 |
| Price to Free Cash Flow | 19.25 |
| Price | 31.49 |
| Earnings Yield | 5.52% |
| Market Cap | 3.847B |
| PEGY Ratio | 1.642 |
| Operating PE Ratio | 14.97 |
| Normalized PE Ratio | 18.28 |